

Table 1. Detection of antiviral drug-resistant viruses in Japan during the 2019/2020 influenza season

as of August 11, 2020

	A(H1N1)pdm09						A(H3N2)						B				
	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir
Resistant (%)	1 ^a (0.12%)	40 ^b (1.6%)	40 ^b (1.6%)	0	0	58 (100%)	0	0	0	0	0	22 (100%)	0	0	0	0	0
Number of viruses tested	831	2,489	2,489	357	357	58	80	82	82	82	82	22	130	139	139	139	139
Number of viruses reported	5,048						130						699				

Baloxavir was examined by focus reduction assay and/or PA sequencing.

NA inhibitors were examined by fluorescence-based NA-Fluor assay, chemiluminescence-based NA-XTD assay, real time RT-PCR allelic discrimination and/or NA sequencing.

Amantadine was examined by M2 sequencing.

^a Patients without treatment 1

^b Patients without treatment 28